²¹¹At-Parthanatine is an Alpha-emitting Radiopharmaceutical therapeutic that targets poly(adenosine-diphosphate-ribose) polymerase 1 (PARP1) in cancer cells. As a therapeutic, ²¹¹At-PTT completes a Theranostic pair with companion diagnostic fluorine-18 Fluorthanatrace (¹⁸F-FTT), which is currently under evaluation in multiple adult cancers for Positron-emission Tomography (PET) Imaging of PARP-1. ²¹¹At-Parthanatine is developed in the indication high-risk neuroblastomas.

Target/Mechanism: PARP1

Carrier/Ligand: Peptide

Radiation Type : Alpha particle (α)